REPROCELL News (3)

REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development

08 March 2022

Read how REPROCELL and IBM developed a novel Machine Learning driven precision medicine strategy for drug development.

REPROCELL spotlights the power of smarter biospecimens in new global publication

21 January 2022

REPROCELL has published an article highlighting the power of biospecimens in EBR. Visit the news section of our website to find out more.

Hoth Therapeutics Extends Partnership Agreement with REPROCELL

25 October 2021

Hoth Therapeutics has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in IBD. Find out why.

Bioserve India to sponsor webinar hosted by the Society of Fetal Medicine

15 September 2021

Find out more about Genetic Testing in Fetal Medicine in the upcoming REPROCELL sponsored webinar by the Society of Fetal Medicine.

REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service

02 September 2021

REPROCELL USA has launched a new service to manufacture GMP iPSC-Master Cell Banks (MCB), compliant with the regulatory standards and guidelines.

REPROCELL signs MSA with TEXCELL for Master Cell Bank Manufacturing

18 August 2021

Read about REPROCELL's Master Service Agreement with TEXCELL JAPAN a TEXCELL Group Company for GMP iPSC - Master Cell Banks (MCB) Manufacturing.

REPROCELL highlights the power of human fresh tissue in global publication

05 July 2021

This article explains the benefits of human fresh tissue testing in drug discovery, describing studies where these assays have helped clinical trials.

REPROCELL's solution for GMP iPSC development - Seed iPSC Manufacturing Suite

29 June 2021

Read more about REPROCELL's new Seed iPSC Manufacture Suite to provide supply for the increasing demand of iPSC-derived Master Cell Banks

REPROCELL Launch New Testing Service for Identification of the Indian (Delta) Covid-19 variant

21 June 2021

Reprocell will launch in Japan a new testing service of identification for Covid-19 variants including India (Delta), UK, South Africa, and Brazil variants

Completion of administration of Stemchymal to all enrolled patients in phase II clinical trial in Japan

24 May 2021

The administrations of Stemchymal have been completed to all enrolled patients in phase II clinical trial for the treatment of SCA in Japan.

VIROCLINICS-DDL announces renewal of collaboration agreement with REPROCELL

18 May 2021

Read more about how REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.

REPROCELL will participate at the Biotechgate Digital Partnering Event.

21 April 2021

This is announcement REPROCELL USA and REPROCELL Europe will be attending Biotechgate Digital Partnering 2021.

19 April 2021 – Bioserve Biotechnologies India Pvt. Ltd. launches clinical oncology diagnostic services in India.

19 April 2021

Read about REPROCELL Bioserve's launch of new clinical oncology diagnostic services featuring NGS-based genomic profiling, targeting a wide range of cancers

Launch of New Testing Service of Identification for Covid-19 Variants

08 April 2021

REPROCELL has launched a new testing service of identification for Covid-19 variants using Allplex SARS-CoV-2 Variants I Assay manufactured by Seegene Inc.

REPROCELL collaborates with Blacktrace Holdings in the sales of Nadia series, single-cell analysis system, in Japan

22 March 2021

Find out more about REPROCELL's collaboration with Blacktrace Holdings Ltd in the domestic sales of their Nadia series: a single-cell analytical system.

REPROCELL Regenerative Medicine Center officially certified as a manufacturing facility for cell culture products

17 March 2021

We are pleased to announce that the REPROCELL Regenerative Medicine Center has been certified as a manufacturing facility for cell culture products.

Hoth Therapeutics Executes Partnership Agreement with REPROCELL to Assess the Effect of HT-003 Therapeutic Platform on Inflammatory Bowel Disease

15 March 2021

Hoth Therapeutics has executed a partnership agreement with REPROCELL to assess the effect of its HT-003 therapeutic platform on tissue from IBD donors.

Corporate News